Treatment of pituitary dwarfism with methionyl human growth hormone in Japan

Endocrinol Jpn. 1986 Oct;33(5):589-96. doi: 10.1507/endocrj1954.33.589.


Sixty-two patients with pituitary dwarfism were treated with three different preparations of methionyl hGH (m-hGH) for 3 to 14 months. They were given 0.5 IU/kg/week intramuscularly. The growth rate during treatment with the three different preparations was the same for each and increased from 3.5 +/- 0.9 to 8.2 +/- 1.7 cm/year. A high incidence of hGH antibody formation was observed following the treatment, but the titer of antibody was decreased according to the purity of m-hGH preparations. At the end of 12 month treatment with a highly purified preparation (Somatonorm III), 76.2% of the patients had hGH antibody. However, the presence of antibodies did not affect the growth rate except in one patient. No clinical or laboratory side-effects were observed following the treatment with m-hGH. Thus, m-hGH was considered to be useful for the treatment of GH deficient children.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Antibody Formation
  • Child
  • Child, Preschool
  • Dwarfism, Pituitary / drug therapy*
  • Female
  • Growth / drug effects
  • Growth Hormone / administration & dosage
  • Growth Hormone / analogs & derivatives*
  • Growth Hormone / immunology
  • Growth Hormone / therapeutic use
  • Human Growth Hormone
  • Humans
  • Injections, Intramuscular
  • Japan
  • Male


  • Human Growth Hormone
  • Growth Hormone